Tag: nintedanib
Tvardi Therapeutics initiates REVERTIPF trial in idiopathic pulmonary fibrosis
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of STAT3 inhibitors, has reached a significant milestone by dosing the first patients in ... Read More
Glenmark Pharmaceuticals gets FDA approval for Nintedanib Capsules
Glenmark Pharmaceuticals Ltd said that it has secured tentative approval from the US Food and Drug Administration (FDA) for Nintedanib Capsules, 100mg, and 150mg. Nintedanib ... Read More